The Center for Epilepsy and Neurodevelopmental Disorders (ENDD)

In early 2023, a $25 million gift from an anonymous donor to Penn Medicine and Children’s Hospital of Philadelphia (CHOP) established the Center for Epilepsy and Neurodevelopmental Disorders (ENDD), accelerating collaborative research in genetic therapies for neurodevelopmental disorders. This gift will bolster the efforts of an interdisciplinary group of clinicians and scientists at Penn and CHOP, led by director Benjamin Prosser, PhD, and co-directors Beverly Davidson, PhD, and Ingo Helbig, MD. Dr. Prosser is an associate professor of Physiology at the University of Pennsylvania’s Perelman School of Medicine, who adjusted the focus of his research career when his own daughter, Lucy, was diagnosed shortly after birth in 2018 with a rare genetic neurodevelopmental disorder.

Benjamin Prosser, PhD, director of the new Center for Epilepsy and Neurodevelopmental Disorders, with his daughter, Lucy, and wife, Erin.

ENDD will initially focus on developing therapies for disorders related to mutations of the STXBP1 and SYNGAP1 genes – which are linked to abnormal brain function, intellectual disability, epilepsy, and motor and behavioral impairments – with the goal of expanding its efforts to other genetic neurodevelopmental disorders over time.

Learn more about the study & how to sign up here. Read the full news release here and watch a special interview with Drs. Prosser and Helbig below.

Webinar announcement for The Center for Epilepsy and Neurodevelopmental Disorders (ENDD)